A Case of Maxillary Sinus Small Cell Carcinoma Treated with CPT-11 and CBDCA Concurrently Combined with Radiation
2015 Volume 144 Pages 84-85
Details
2015 Volume 144 Pages 84-85
Objective: Extrapulmonary small cell carcinoma (EPSCC) is a cancer with a poor prognosis. The treatment of EPSCC has not been established because of its rarity. We encountered a case of EPSCC involving the maxillary sinus, which had been treated with irinotecan (CPT-11), carboplatin (CBDCA) and radiotherapy.
Case report: A-79-year-old woman visited our clinic with bloody rhinorrhea and nasal obstruction. Physical examination revealed a rough nasal polyp in the left nasal cavity. CT scans revealed a soft tissue shadow in the left maxillary sinus. Endoscopic sinus surgery was performed. The nasal polyp was pathologically diagnosed as a small cell carcinoma. There was no evidence of metastasis, and the tumor was staged as maxillary cancer, T2N0M0. Chemotherapy with CPT-11 combined with CBDCA and radiotherapy (total 50 Gy) were started. After 3 cycles, the chemotherapy was discontinued due to severe anemia. The CT scan at this time demonstrated no signs of tumor progression. The disease has remained stable with no recurrence for 3 year and 6 months.
Discussion: Recently, some articles about extensive-disease small cell lung carcinoma have shown that the IP therapy comprising CPT-11 combined with platinum, is more effective than the EP therapy comprising etoposide and platinum. However, for limited-disease small cell lung cancer, the IP therapy combined with thoracic radiotherapy is not indicated in general, due to its severe toxicity such as radiation pneumonitis. However, for EPSCC, the IP therapy with radiotherapy can possibly be performed more safely, because radiation for EPSCC does not target the lungs. In the present case, no severe side effect developed except for anemia, suggesting the usefulness of the IP therapy combined with radiotherapy for EPSCC.
Conclusion: We present herein on a case of EPSCC treated with chemoradiotherapy with CPT-11 and CBDCA. Tumor growth has been controlled for the period of 3 year and 6 months.
